<DOC>
	<DOC>NCT00777959</DOC>
	<brief_summary>This study will look to see if the combination of ridaforolimus and bicalutamide works better than placebo and bicalutamide in men with prostate cancer.</brief_summary>
	<brief_title>Bicalutamide and Ridaforolimus in Men With Prostate Cancer (MK-8669-002)</brief_title>
	<detailed_description>Ridaforolimus (MK8669/AP23573) was also known as deforolimus until May 2009.</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Confirmed adenocarcinomas of the prostate. Evidence of metastatic disease Evidence of disease progression including one of the following: increasing levels of PSA, progressive lymph node disease, or worsening bone scan PSA level is greater or equal to 7 ng/ml. ECOG performance status less than or equal to 1 Exclusion Criteria : Previously received bicalutamide, flutamide, or nilutamide within the past 12 months (except for a period of use less than 30 days long). Prior chemotherapy for prostate cancer Prior rapamycin or rapamycin analogs, including ridaforolimus, everolimus, or temsirolimus. Patient is receiving an opioid or narcotic analgesic for pain due to prostate cancer Patient has pain related to prostate cancer that warrants the initiation of chemotherapy</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>